Phase 3Completed

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)

Sponsor
Maxim Pharmaceuticals (Industry)
Enrollment
360 planned
Conditions
Leukemia
Interventions
aldesleukin; histamine dihydrochloride
Ages
adults, older adults
Registry
NCT00003991

Full record on ClinicalTrials.gov

From the registry

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission. PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.

History

  1. Last registry update

  2. Study completion

  3. Registered

  4. Started